Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 1069 record(s)

Req # A-2023-000126

Adverse Drug Reactions (ADRs). Report numbers: E2B_00675714, E2B_02977829, E2B_03128456.

Organization: Health Canada

82 page(s)
January 2024

Req # A-2023-000256

Adverse Drug Reactions (ADRs). Report numbers: E2B_06091444, E2B_06055782, E2B_06090605, E2B_01299090, E2B_06054585, 001002529, E2B_06051301, E2B_03433916, 001023397, 001024211.

Organization: Health Canada

239 page(s)
January 2024

Req # A-2023-000331

Adverse Drug Reactions (ADRs). Report numbers: E2B_06001457, E2B_02939494, E2B_06179026, 001034493, E2B_001035027.

Organization: Health Canada

122 page(s)
January 2024

Req # A-2023-000758

Adverse Drug Reactions (ADRs). Report numbers: E2B_03583301, E2B_06442226, E2B_06413944, E2B_06442785, E2B_06438176, E2B_06452366, E2B_06421208, E2B_06428678, E2B_06418609.

Organization: Health Canada

155 page(s)
January 2024

Req # A-2023-000763

Adverse Drug Reactions (ADRs). Report numbers: E2B_06425916, E2B_06426700, E2B_06428262, E2B_06428379.

Organization: Health Canada

55 page(s)
January 2024

Req # A-2023-000779

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102700- 258.

Organization: Health Canada

29 page(s)
January 2024

Req # A-2023-000784

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106488-990.

Organization: Health Canada

23 page(s)
January 2024

Req # A-2023-000836

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-101473-308.

Organization: Health Canada

21 page(s)
January 2024

Req # A-2023-000837

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103099-693.

Organization: Health Canada

25 page(s)
January 2024

Req # A-2023-000847

Adverse Drug Reactions (ADRs) for Tavneos. Report numbers: E2B_06476280, E2B_06503137. ADR for Rexulti: E2B_06469898. ADR for Rexulti. Report number: E2B_06469898. ADR for Rexulti and Aripiprazole. Report number: E2B_06501539. ADRs for Ablify Maintena. Report numbers: 001048638, 001048913, 001050459, 001050957, 001051278. ADR for Aripiprazole. Report number: E2B_06507796.

Organization: Health Canada

121 page(s)
January 2024
Date modified: